lates, have not been determined in patients with STEMI. In addition, although prior studies have suggested that treatment with glycoprotein IIb/IIIa inhibitors (GPIs) may reduce stent thrombosis with BMS 18 and that premature thienopyridine discontinuation is associated with a higher risk of stent thrombosis, 19 the optimal pharmacological regimen to ameliorate stent thrombosis has not been determined from a contemporary large randomized trial.
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In the prospective, multicenter, randomized Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, 3602 patients with STEMI undergoing primary PCI were randomized to varying pharmacological regimens and DES versus BMS, representing the largest stent study in patients with STEMI to date. 20 We therefore sought to evaluate the frequency and predictors of stent thrombosis occurring within the first 2 years after stent implantation in patients with STEMI from the HORIZONS-AMI trial.
Methods
The HORIZONS-AMI trial design has been described previously in detail. 20 In brief, HORIZONS-AMI was a prospective, open-label, randomized, multicenter trial that enrolled patients with STEMI presenting within 12 hours after the onset of symptoms. A total of 3602 patients at 123 centers in 11 countries were randomized (1:1) to unfractionated heparin (UFH) plus a GPI or bivalirudin monotherapy. After angiography, 3006 patients were then randomized again (3:1) to either TAXUS Express 2 paclitaxel-eluting stents (PES) or otherwise identical BMS (both Boston Scientific, Natick, MA). Clinical follow-up was prespecified at 30 days, 6 months, 1 year, and yearly thereafter for a total of 5 years in all patients. The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed an informed consent form.
Medications
Unfractionated heparin was administered intravenously as 60 IU/kg bolus with subsequent boluses to achieve an activated clotting time of 200 to 250 seconds. Bivalirudin was administered as an intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg per hour. Both antithrombin agents were discontinued per protocol at the completion of angiography or PCI, but could be continued at low doses if required per operator discretion. Glycoprotein IIb/IIIa inhibitors were to be administered before PCI in all patients in the UFH plus GPI arm, and were allowed by protocol in the bivalirudin arm only for refractory no reflow or giant thrombus after PCI. The only anticoagulant permitted before study drug initiation was UFH.
Aspirin 324 mg chewed or 500 mg intravenous was given in the emergency department, followed by 300 to 325 mg orally daily during the hospitalization and 75 to 81 mg daily indefinitely thereafter. A clopidogrel loading dose (either 300 or 600 mg per investigator discretion) was administered before catheterization, followed by 75 mg orally daily for at least 6 months; dual antiplatelet therapy was recommended for at least 1 year.
Stent Thrombosis
Stent thrombosis was classified according to the Academic Research Consortium definition as definite or probable. 21 Stent thrombosis occurring within 24 hours was defined as acute; Ͼ24 hours to 30 days was defined as subacute; from Ͼ30 days to 1 year was defined as late; and Ͼ1 year was defined as very late. Early stent thrombosis was defined as occurring within 30 days (ie, acute plus subacute). All adverse events, including stent thrombosis, were adjudicated by an independent clinical events committee blinded to pharmacology and stent assignment after review of original source documentation.
Quantitative Coronary Angiography
An independent angiographic core laboratory assessed all angiograms blinded to treatment assignment for baseline and final lesion and flow characteristics with the use of validated quantitative methods. 22
Statistical Analysis
The present analysis is restricted to patients in whom at least 1 stent was implanted during the index procedure. Categorical variables were compared by 2 analysis or Fisher exact test. Continuous variables are expressed as median and interquartile ranges and were compared by the Wilcoxon rank sum test. Kaplan-Meier methods were used to derive the event rates at follow-up and to plot time-to-event curves; comparisons were made with the log-rank test. Landmark analysis was performed to assess events occurring in different time periods. Cox proportional hazards analysis was used to identify the independent predictors of stent thrombosis via stepwise regression. The P value to enter and exit the model was 0.05. The following covariates were considered in the model: (1) clinical and laboratory variables: age, sex, enrollment in the United States, current smoking, history of insulin-dependent diabetes mellitus, previous PCI, previous coronary artery bypass grafting, history of myocardial infarction (MI), history of congestive heart failure, history of peripheral vascular disease, Killip class, baseline anemia and platelet count, baseline renal insufficiency (estimated creatinine clearance Ͻ60 mL/min), and anterior MI; (2) pharmacological variables: bivalirudin (versus UFH plus GPI), prerandomization UFH use, preadmission aspirin and thienopyridine use, clopidogrel loading dose, and thienopyridine discontinuation (entered into the model as a time-updated covariate); (3) procedural variables: any DES implanted (versus only BMS), direct stenting attempted, postdilation balloon used, maximum balloon pressure; and (4) angiographic variables: baseline reference vessel diameter, baseline thrombus grade, ulceration, aneurysm, Thrombolysis in Myocardial Infarction (TIMI) flow, bifurcation lesion, moderate/severe calcification, multiple vessels treated, total lesion length, and final TIMI flow. Lesion level variables were summarized as worst case per patient if multiple lesions were present. All statistical tests were 2-tailed. Statistical significance was set at a level of 0.05.
Results

Patients, Procedures, and Stent Thrombosis
Between March 25, 2005 , and May 7, 2007, 3602 patients with STEMI undergoing primary PCI were enrolled and randomized to UFH plus GPI (nϭ1802) or bivalirudin monotherapy (nϭ1800). After angiography, PCI was performed in 3345 patients (92.9%), among whom stenting was performed in 3226 (96.4%). Among those patients undergoing primary stenting, 3006 (93.2%) were randomized to receive PES (nϭ2257) or BMS (nϭ749), and stent type was determined in the remainder by operator discretion. Stents were implanted in a total of 3202 patients (comprising the current study cohort), including 2261 patients who received 1 or more DES (97.6% of which were PES) and 861 patients who received only BMS ( Figure 1 ). Two-year follow-up was available in 3054 of 3202 patients (95.4%), including 2162 of 2261 DES patients (95.6%) and 829 of 872 BMS patients (95.1%).
Among the 3202 stented patients, 142 definite or probable stent thrombosis events occurred in 137 patients (4.4%) within the 2-year follow-up period, 119 (83.8%) of which were definite stent thrombosis. By landmark analysis, acute stent thrombosis occurred in 28 patients (0.9%); subacute stent thrombosis occurred in 49 patients (1.6%); late stent thrombosis occurred in 32 patients (1.0%); and very late stent thrombosis occurred in 33 patients (1.1%).
Predictors of Stent Thrombosis
The univariate clinical, angiographic, procedural, and pharmacological correlates of definite/probable stent thrombosis appear in Tables 1 through 4 . Compared with patients without stent thrombosis, those with stent thrombosis at any time point within the 2-year follow-up period were younger and had a higher rate of insulin-treated diabetes mellitus, current smoking, prior MI, prior PCI, and higher baseline platelet count. Other baseline demographic and laboratory features were comparable between those with and without stent thrombosis ( Table 1) . Lesions with stent thrombosis were more likely to be aneurysmal, to have a larger baseline thrombus burden, and to have a greater residual stenosis after the procedure (Tables 2 and 3 ). Stent thrombosis was also associated with a significantly higher prevalence of baseline and postprocedural TIMI flow 0/1 (and a lower corrected TIMI frame count).
Patients (both randomized and nonrandomized) who received 1 or more DES compared with only BMS had nearly identical 2-year cumulative rates of definite/probable stent thrombosis (4.4% in both groups; Table 1 and Figure 2 ). There was not a significant difference between DES and BMS in the rates of definite stent thrombosis at 2 years (3.9% versus 3.6%; Pϭ0.71). Similarly, among the randomized PES versus BMS cohort in whom 1 or more stents were implanted (nϭ2982), the 2-year rates of definite/probable and definite stent thrombosis were 4.4% versus 4.1% (Pϭ0.76) and 3.9% versus 3.6% (Pϭ0.71), respectively. Among all stented patients, the respective landmark rates of definite/probable acute stent thrombosis (0.9% versus 0.6%; Pϭ0.33), subacute stent thrombosis (1.3% versus 2.1%; Pϭ0.14), late stent thrombosis (1.1% versus 0.7%; Pϭ0.31), and very late stent thrombosis (1.2% versus 1.0%; Pϭ0.69) were not significantly different between the DES and BMS groups.
Among patients randomized to bivalirudin monotherapy versus UFH plus GPI (Table 4 and Figure 3 ), there were no significant differences in the 2-year rates of definite/probable stent thrombosis (4.3% versus 4.6%, respectively; Pϭ0.73) or definite stent thrombosis (3.9% versus 3.8%, respectively; Pϭ0.71). Patients with stent thrombosis compared with those without stent thrombosis less frequently received a preproce- dural loading dose of clopidogrel 600 mg ( Table 4 ). The high loading dose mainly impacted subacute thrombosis ( Figure 4 ).
Predictors of Interval Stent Thrombosis
As shown in Table 5 , the independent predictors of acute, subacute, late, and very late stent thrombosis differed. Acute stent thrombosis (within 24 hours) was more common in ulcerated lesions and in vessels with baseline TIMI 0/1 flow, in younger patients, in patients randomized to bivalirudin rather than UFH plus GPI, and in those not receiving prerandomization UFH. The multivariable predictors of subacute stent thrombosis (from 24 hours to 30 days) included insulin-treated diabetes mellitus, history of congestive heart failure, baseline platelet count, baseline and final TIMI 0/1 flow, and nonuse of a 600-mg loading dose of clopidogrel ( Figure 4 ). Cigarette smoking and prior MI were the only independent predictors of late stent thrombosis (occurring between 1 month and 1 year), whereas only insulin-treated diabetes mellitus, prior PCI, baseline platelet count, and use of UFH plus GPI rather than bivalirudin predicted very late stent thrombosis (occurring between 1 and 2 years). The independent predictors of early stent thrombosis (Ͻ30 days) and of late plus very late stent thrombosis (30 days to 2 years) and of the cumulative 2-year stent thrombosis are also summarized in Table 5 .
Bivalirudin and Interval Stent Thrombosis
As shown in Figure 5 , acute stent thrombosis occurred more frequently in patients assigned to bivalirudin compared with heparin plus GPI (1.4% versus 0.3%; PϽ0.001); this difference (nϭ20 excess events) was evident almost entirely within the first 5 hours after stent implantation ( Figure 5 ). Conversely, stent thrombosis after 24 hours occurred less frequently in patients with bivalirudin compared with heparin plus GPI (2.8% versus 4.4%; Pϭ0.02). Prerandomization UFH was protective from the occurrence of cumulative stent 
Dangas et al Stent Thrombosis in Acute Myocardial Infarction
thrombosis through 2 years and especially acute stent thrombosis ( Figure 5 ), an effect that was numerically more pronounced in bivalirudin-assigned patients (nonsignificant P interaction ϭ0.39).
Among 775 heparin plus GPI-treated patients who received both prerandomization heparin and a 600-mg loading dose of clopidogrel, the acute, subacute, late, very late, and 2-year cumulative rates of stent thrombosis were 0.1% (1), 1.6% (12), 1.4% (10), 1.2% (8), and 4.1% (30), respectively. Among 708 bivalirudin-treated patients who received both prerandomization heparin and a 600-mg loading dose of clopidogrel, the acute, subacute, late, very late, and 2-year cumulative rates of stent thrombosis were 0.7% (5), 0.6% (4), 0.9% (6), 0.8% (6), and 2.8% (20) , respectively.
Role of Clopidogrel Loading Dose
Within the entire patient population, clopidogrel loading dose of 300 mg versus 600 mg had no significant effect on acute stent thrombosis (0.8% versus 0.8%; Pϭ0.92), but the higher loading dose (600 mg) was associated with a 48% decrease in subacute stent thrombosis rates ( Table 5 ). Among GPI-treated patients who received a 300-or 600-mg loading dose of clopidogrel, the acute (0.0% versus 0.4%; Pϭ0.14) and subacute (2.6% versus 1.5%; Pϭ0.14) stent thrombosis rates were similar between the 2 groups. Among bivalirudintreated patients who received a 300-or 600-mg loading dose of clopidogrel, the acute (1.7% versus 1.2%; Pϭ0.41) stent thrombosis rates were similar between the groups, whereas the subacute (2.6% versus 1.5%; Pϭ0.14) stent thrombosis rates were lower with a 600-mg loading dose of clopidogrel (Figure 4 ).
Discussion
The principal findings from this large-scale, prospective, randomized trial of patients with STEMI undergoing stent implantation are as follows: (1) Academic Research Consortium definite/probable stent thrombosis within 2 years was a relatively common event, occurring in 4.4% of patients and evenly distributed among the acute, subacute, late, and very late time periods; (2) the type of stent implanted (DES versus BMS) was not related to stent thrombosis during any time interval up to 2 years, including very late stent thrombosis;
(3) stent thrombosis within 2 years occurred with similar frequency in patients treated with UFH plus GPI and bivalirudin monotherapy; however, acute stent thrombosis was more common with bivalirudin, whereas stent thrombosis after 24 hours was more common with UFH plus GPI; and (4) independent predictors of early stent thrombosis were higher baseline platelet count, insulin-treated diabetes mellitus, no administration of prerandomization UFH, angiographic ulceration, and baseline TIMI 0/1 flow. The independent predictors of late and very late stent thrombosis (30 days to 2 years) were higher baseline platelet count, current smoking, insulintreated diabetes mellitus, and prior PCI. A 600-mg clopi- dogrel loading dose was an independent predictor of reduced subacute stent thrombosis.
Incidence of Stent Thrombosis and Impact of Stent Type
Although it is a relatively low-frequency event, stent thrombosis is associated with a high risk of MI and death. 14, 23 Emerging data suggest that STEMI presentation is one of the most powerful predictors of stent thrombosis. In the Swedish Coronary Angiography and Angioplasty Registry, 17 the risk of stent thrombosis in STEMI was increased 2.5-fold relative to patients without STEMI. In the present study, the rate of early stent thrombosis (within 30 days) was 2.5%, which was substantially higher than the 0.1% to 0.6% early stent thrombosis rates reported from the randomized controlled trials of DES in patients with stable coronary artery disease 6, 8, 11 and higher than the 1.5% early stent thrombosis rate reported in moderate-and high-risk patients with non-STEMI in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 24 In HORIZONS-AMI, the definite/probable stent thrombosis rate within 1 year of STEMI PCI was 3.4% (nϭ107). Before this study, the reported 1-year rates of stent thrombosis in STEMI from several modest-sized randomized trials of DES versus BMS ranged from Ϸ1% 3 to as high as 3% to 4%. 25, 26 The present large-scale study not only establishes that stent thrombosis within 1 year after PCI in STEMI is indeed a relatively frequent occurrence, but also that Ϸ0.8% of patients have an additional stent thrombosis episode between 1 and 2 years, which is a materially higher ongoing rate than the Ϸ0.3%/y to 0.4%/y incidence of very late stent thrombosis described previously from non-STEMI populations. 17, 27 Finally, the overall 2-year cumulative stent thrombosis rate of 4.4% in the present study is substantially higher than the reported rates of Ϸ1.3% and Ϸ2.5% in patients without STEMI from randomized trials 8, 11, 27 and a large multicenter all-comers' experience. 28 Unlike most previous studies, we reported stent thrombosis rates based on the initially treated population and not only among patients who achieved an "angiographically optimal result."
The high frequency of stent thrombosis after STEMI may be related to the underlying plaque composition responsible for MI and the subsequent vascular responses to stents. Stent strut penetration of an underlying necrotic core may augment inflammation and fibrin deposition and inhibit neointimal growth, resulting in uncovered stent struts, especially with DES. 12 Reduced epicardial flow, vasoconstriction, and concerns about embolizing thrombus and friable atheroma may lead to stent undersizing, with incomplete stent apposition and underexpansion during the index procedure. Moreover, the incidence of positive arterial remodeling and late acquired incomplete stent apposition is higher is patients with acute coronary syndrome and STEMI compared with those with non-acute coronary syndrome, especially after DES. 29, 30 However, although the present study found that lesion ulceration and aneurysm were strong predictors of stent thrombosis, no differences in the rate of stent thrombosis at any time interval up to 2 years were noted between DES and BMS. Although it is possible that even the present large-scale study was underpowered to detect a difference in stent thrombosis between DES and BMS, the observed lack of a significant difference is supported by a meta-analysis of 11 STEMI studies with 7352 randomized STEMI patients (including HORIZONS-AMI) that found no difference in the rates of stent thrombosis between DES and BMS to 1 year. 7 In HORIZONS-AMI, even very late stent thrombosis (between 1 and 2 years), although frequent with both stent types, was not significantly more common with DES than BMS. In this regard, the relatively high 0.7% very late stent thrombosis rate documented between 1 and 2 years with BMS in the present study is notable and refutes prior conceptions 9,11 that very late stent thrombosis after BMS is a rare phenomenon (at least in STEMI). Nonetheless, because DES may delay vascular healing for long periods of time, 12 even longer-term 
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follow-up is needed before all late safety concerns specific to DES in STEMI are dismissed.
Impact of Antithrombotic Medication Use
The HORIZONS-AMI trial demonstrated that use of bivalirudin rather than UFH plus GPI in patients with STEMI undergoing primary PCI markedly reduced hemorrhagic complications, transfusions, and thrombocytopenia and, as a result, significantly improved overall and cardiac survival. 20, 31 Nonetheless, we previously reported that stent thrombosis was increased with bivalirudin use within 24 hours, although not by 30 days or 1 year. 20, 31 The present study extends these findings; with follow-up to 2 years, stent thrombosis occurred in 4.3% of bivalirudin-treated patients and 4.6% of UFH plus GPI-treated patients (Pϭ0.73). Indeed, stent thrombosis in patients treated with bivalirudin occurred significantly less frequently than with UFH plus GPI after the 24-hour period, and randomization to bivalirudin was a significant multivariable predictor of a 54% reduction in very late stent thrombosis. The fact that an excess of 20 acute stent thrombosis events with bivalirudin was evident within 5 hours of the procedure, was unrelated to clopidogrel loading dose, and was reduced by prerandomization heparin administration raises the follow- ing possible pharmacodynamic explanation: The fast reversal of bivalirudin (within 1 to 2 hours) at a time frame in which the oral clopidogrel has not yet achieved adequate platelet inhibition (Ϸ6 hours) may leave the patient without an active antithrombotic, especially if the final result might be suboptimal, which can happen frequently in acute MI (reduced blush grade, TIMI flow Ͻ3, minor dissections, residual microthrombi in the coronary arteries, predisposition to spasm); in this context, the more intense anticoagulation and antiplatelet regimen including early heparin use and a GPI infusion may delay the time course of stent thrombosis. Although chance as an explanation for this finding cannot be excluded, in prior studies the prevention of bleeding by bivalirudin was also strongly associated with a reduction in late as well as early mortality, 32 and the same may be true for late stent thrombosis (which may explain in part the late survival benefit of bivalirudin). Regardless, the excess risk of acute stent thrombosis with bivalirudin compared with UFH plus GPI, as well as the comparable total rates of cumulative stent thrombosis at 30 days and beyond, must be placed in perspective with the substantial reduction in all-cause and cardiac mortality achieved by preventing hemorrhagic complications with this regimen.
Nonetheless, the significance of the absolute 1% increased rate of stent thrombosis within the first 5 hours after randomization to bivalirudin rather than UFH plus GPI should not be minimized, especially because alternative methods can be used in this limited time period (eg, prolonged infusion of Figure 5 . Landmark analyses (0 to 24 hours and 1 day to 2 years) of stent thrombosis according to the randomization assignment to antithrombin therapy (A) and the administration of prerandomization heparin (B). Relationship between administration of heparin before randomization to stent thrombosis in all patients within 24 hours in each of the randomized groups (C). HR indicates hazard ratio; CI, confidence interval; UFH, unfractionated heparin; GP, glycoprotein; GPI, glycoprotein IIb/IIIa inhibitor; and Def/Prob, definite/probable.
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bivalirudin in acute MI cases, heparin bolus in the emergency department or ambulance, use of a faster-acting antiplatelet such as prasugrel instead of clopidogrel) after appropriate clinical testing. The present study suggests that optimizing adjunct pharmacology may mitigate this risk. Prerandomization UFH was a powerful independent predictor of freedom from acute and 2-year cumulative stent thrombosis, and a 600-mg loading dose of clopidogrel was protective from subacute stent thrombosis. The potential reasons why a higher loading dose of clopidogrel may reduce early stent thrombosis in STEMI are not difficult to discern. A 600-mg compared with a 300-mg loading dose of clopidogrel consistently leads to greater platelet inhibition, acts more rapidly, 33 and has been associated with lower ischemic event rates in other STEMI studies in addition to HORIZONS-AMI. 34 Even more rapidly acting and potent blockade of the ADP platelet receptor further reduces early stent thrombosis in acute coronary syndrome and STEMI, although it increases major bleeding not related to surgery. 35, 36 Bivalirudin has not to date been studied with either prasugrel or ticagrelor, although such a combination should theoretically provide synergistic benefits.
The mechanisms underlying the reduction in stent thrombosis (both early and late) with prerandomization UFH are less clear. Whether this effect is due to greater and/or more prolonged antithrombin inhibition resulting in more profound suppression of thrombin generation, thereby facilitating clot dissolution, is unknown, but deserves further study. It is also possible that this correlate remained in the final multivariable model because of confounding. Additional investigation is also warranted to determine whether a prolonged bivalirudin infusion (eg, 4 to 6 hours) after PCI (with or without prasugrel or ticagrelor) might further reduce acute stent thrombosis (without increasing bleeding).
Limitations
Although HORIZONS-AMI is the largest comparative DES versus BMS study to date and the cumulative stent thrombosis rate to 2 years was relatively high, even this trial was not powered to completely exclude a small difference in stent thrombosis between stent types or pharmacological regimens. We also cannot be sure that all multivariable correlates of stent thrombosis were identified, especially in each discrete time interval given the reduced number of events and colinearity between some variables. Although the present analysis is post hoc and therefore hypothesis generating, the adjudication of stent thrombosis events was prospective and rigorous, assessed by a committee blinded to drug and stent use with concurrent review of original source documents and angiograms. Particular caution is warranted, however, regarding observations with nonrandomized treatments, such as selection of clopidogrel loading dose and prerandomization UFH use, given the possibility for residual confounding.
Conclusions
The 2-year results from the large-scale, international HORIZONS-AMI trial suggest that stent thrombosis occurs relatively frequently within 2 years after primary PCI in STEMI, although with comparable rates with DES and BMS and with bivalirudin and UFH plus GPI. Optimizing adjunct pharmacology with early antithrombin therapy and preloading with a potent platelet ADP antagonist, may reduce early stent thrombosis and further improve prognosis in these high-risk patients.
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